Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)

NCT02474927 is registered in ClinicalTrials.gov with John F. McDyer, MD as lead sponsor.

NCT NCT02474927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02474927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)
Lead sponsor
John F. McDyer, MD
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2015
Completion date
July 26, 2021
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung transplant rejection